KR102792113B1 - Stat3 억제제 - Google Patents

Stat3 억제제 Download PDF

Info

Publication number
KR102792113B1
KR102792113B1 KR1020207033270A KR20207033270A KR102792113B1 KR 102792113 B1 KR102792113 B1 KR 102792113B1 KR 1020207033270 A KR1020207033270 A KR 1020207033270A KR 20207033270 A KR20207033270 A KR 20207033270A KR 102792113 B1 KR102792113 B1 KR 102792113B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
disease
fibrosis
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207033270A
Other languages
English (en)
Korean (ko)
Other versions
KR20210011925A (ko
Inventor
소피아 드 아차발 위드
윌리엄 이 바우타
윌리엄 알 주니어 캔트렐
데이비드 존 트워디
Original Assignee
트발디 테라퓨틱스, 인크.
베일러 칼리지 오브 메디신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트발디 테라퓨틱스, 인크., 베일러 칼리지 오브 메디신 filed Critical 트발디 테라퓨틱스, 인크.
Publication of KR20210011925A publication Critical patent/KR20210011925A/ko
Application granted granted Critical
Publication of KR102792113B1 publication Critical patent/KR102792113B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020207033270A 2018-04-19 2019-04-18 Stat3 억제제 Active KR102792113B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659872P 2018-04-19 2018-04-19
US62/659,872 2018-04-19
US201962793491P 2019-01-17 2019-01-17
US62/793,491 2019-01-17
PCT/US2019/028135 WO2019204614A1 (en) 2018-04-19 2019-04-18 Stat3 inhibitors

Publications (2)

Publication Number Publication Date
KR20210011925A KR20210011925A (ko) 2021-02-02
KR102792113B1 true KR102792113B1 (ko) 2025-04-04

Family

ID=68240338

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207033270A Active KR102792113B1 (ko) 2018-04-19 2019-04-18 Stat3 억제제

Country Status (18)

Country Link
US (2) US11826315B2 (https=)
EP (2) EP3773537B1 (https=)
JP (1) JP7411315B2 (https=)
KR (1) KR102792113B1 (https=)
CN (1) CN112367984B (https=)
AU (1) AU2019255755B2 (https=)
BR (1) BR112020021329A2 (https=)
DK (1) DK3773537T3 (https=)
ES (1) ES2911428T3 (https=)
HU (1) HUE059318T2 (https=)
IL (1) IL278112B2 (https=)
MX (1) MX2020011065A (https=)
MY (1) MY207195A (https=)
PH (1) PH12020551728A1 (https=)
PL (1) PL3773537T3 (https=)
PT (1) PT3773537T (https=)
SG (1) SG11202010347XA (https=)
WO (1) WO2019204614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
CN114761405A (zh) * 2019-11-29 2022-07-15 南京明德新药研发有限公司 抗hbv的1,7-萘啶类化合物
JP2023504194A (ja) * 2019-12-03 2023-02-01 ベイラー カレッジ オブ メディスン インスリン耐性における使用方法のための治療化合物
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
AR128676A1 (es) * 2022-03-01 2024-06-05 Tvardi Therapeutics Inc Compuestos terapéuticos, formulaciones, uso y método de preparación
US20250170079A1 (en) * 2022-03-04 2025-05-29 Tvardi Therapeutics, Inc. Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer
CA3254067A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. STAT3 INHIBITOR MEDICINES
TW202412749A (zh) * 2022-07-21 2024-04-01 美商特梵迪治療股份有限公司 治療性化合物、調配物、及其用途
EP4633620A1 (en) * 2022-12-12 2025-10-22 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of non-viral liver cancer
WO2025184497A1 (en) * 2024-02-29 2025-09-04 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149192A1 (en) 2008-06-04 2009-12-10 Baylor College Of Medicine Stat3 inhibitors
CN102766103A (zh) * 2012-07-24 2012-11-07 齐鲁制药有限公司 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
US20150031714A1 (en) 2013-07-18 2015-01-29 Baylor College Of Medicine Methods and compositions for prevention of allergic reaction
WO2017083719A1 (en) 2015-11-13 2017-05-18 William Marsh Rice University Transition metal free methods of synthesis of biaryl compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4279909A (en) 1980-02-13 1981-07-21 Fujisawa Pharmaceutical Co., Ltd. Antiallergic method
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
CA2413878A1 (en) 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
US20050287664A1 (en) 2004-05-27 2005-12-29 Ming-Ji Fann Cellular proliferation control factors
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
US20100035793A1 (en) 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CA2636909A1 (en) 2006-01-13 2007-07-26 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production with tanshinones
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
US20090264353A1 (en) 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010080581A2 (en) 2008-12-19 2010-07-15 The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
US9891213B2 (en) 2009-01-12 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Granulocyte-based methods for detecting and monitoring immune system disorders
CA2781706A1 (en) * 2009-11-24 2011-06-03 The Ohio State University Transcription factor inhibitors and related compositions, formulations and methods
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20140371188A1 (en) 2011-11-23 2014-12-18 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
AU2014290363B2 (en) * 2013-07-18 2019-02-21 Baylor College Of Medicine Methods and compositions for treatment of fibrosis
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
US11026905B2 (en) * 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149192A1 (en) 2008-06-04 2009-12-10 Baylor College Of Medicine Stat3 inhibitors
CN102766103A (zh) * 2012-07-24 2012-11-07 齐鲁制药有限公司 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
US20150031714A1 (en) 2013-07-18 2015-01-29 Baylor College Of Medicine Methods and compositions for prevention of allergic reaction
WO2017083719A1 (en) 2015-11-13 2017-05-18 William Marsh Rice University Transition metal free methods of synthesis of biaryl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [Online], CAS Registry Number: 36062-33-6, 518302-82-4, 518302-80-2, 518302-79-9, 518302-76-6, 518302-75-5, 518302-74-4, 518302-73-3, 518302-69-7, 518302-68-6 외 4건*

Also Published As

Publication number Publication date
CN112367984A (zh) 2021-02-12
ES2911428T3 (es) 2022-05-19
MY207195A (en) 2025-02-05
KR20210011925A (ko) 2021-02-02
JP7411315B2 (ja) 2024-01-11
US20240058284A1 (en) 2024-02-22
US11826315B2 (en) 2023-11-28
AU2019255755A1 (en) 2020-12-03
BR112020021329A2 (pt) 2021-04-27
IL278112B2 (en) 2023-07-01
JP2021521243A (ja) 2021-08-26
EP3773537A1 (en) 2021-02-17
US20210114980A1 (en) 2021-04-22
IL278112B1 (en) 2023-03-01
PL3773537T3 (pl) 2022-05-23
PT3773537T (pt) 2022-04-19
AU2019255755B2 (en) 2024-07-25
MX2020011065A (es) 2021-01-20
EP4070790A1 (en) 2022-10-12
SG11202010347XA (en) 2020-11-27
HUE059318T2 (hu) 2022-11-28
CA3097403A1 (en) 2019-10-24
PH12020551728A1 (en) 2021-06-14
IL278112A (https=) 2020-12-31
EP3773537B1 (en) 2022-03-23
CN112367984B (zh) 2024-05-10
EP3773537A4 (en) 2021-05-26
DK3773537T3 (en) 2022-04-25
WO2019204614A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
KR102792113B1 (ko) Stat3 억제제
US11026905B2 (en) STAT3 inhibitors
US9604988B2 (en) Agent for treating or inhibiting recurrence of acute myeloid leukemia
US20080287462A1 (en) New compounds 834
CN117886813A (zh) Shp2磷酸酶变构抑制剂
EP3183251A1 (en) Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
JP2017530147A (ja) ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
JP7681059B2 (ja) ヤーヌスキナーゼ（ｊａｋ）ファミリー阻害剤及びその調製と使用
WO2019204427A1 (en) Methods for measuring and stabilizing stat3 inhibitors
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
WO2022206705A1 (zh) 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
WO2022005961A1 (en) Prpk inhibitors
JP2021514399A (ja) Ｅｇｆｒの阻害剤およびその使用法
CA3097403C (en) Stat3 inhibitors
TW202506118A (zh) 雜環炔基取代的醯胺衍生物、其製備方法及其應用
HK40073672A (en) Stat3 inhibitors
EA043779B1 (ru) Ингибиторы stat3
HK40038526A (en) Stat3 inhibitors
HK40038526B (en) Stat3 inhibitors
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
CA3088801A1 (en) Compounds for treating rac-gtpase mediated disorder
JP2020055752A (ja) ジベンゾジアゼピン誘導体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220407

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240514

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250106

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250402

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250402

End annual number: 3

Start annual number: 1

PG1601 Publication of registration